BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 24043542)

  • 21. The unique nature of the serine interactions for alpha 1-adrenergic receptor agonist binding and activation.
    Hwa J; Perez DM
    J Biol Chem; 1996 Mar; 271(11):6322-7. PubMed ID: 8626427
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tyrosine 308 is necessary for ligand-directed Gs protein-biased signaling of β2-adrenoceptor.
    Woo AY; Jozwiak K; Toll L; Tanga MJ; Kozocas JA; Jimenez L; Huang Y; Song Y; Plazinska A; Pajak K; Paul RK; Bernier M; Wainer IW; Xiao RP
    J Biol Chem; 2014 Jul; 289(28):19351-63. PubMed ID: 24831005
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative molecular field analysis of fenoterol derivatives: A platform towards highly selective and effective beta(2)-adrenergic receptor agonists.
    Jozwiak K; Woo AY; Tanga MJ; Toll L; Jimenez L; Kozocas JA; Plazinska A; Xiao RP; Wainer IW
    Bioorg Med Chem; 2010 Jan; 18(2):728-36. PubMed ID: 20036561
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular modeling of A1 and A2A adenosine receptors: comparison of rhodopsin- and beta2-adrenergic-based homology models through the docking studies.
    Yuzlenko O; Kieć-Kononowicz K
    J Comput Chem; 2009 Jan; 30(1):14-32. PubMed ID: 18496794
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular basis for stereoselective transport of fenoterol by the organic cation transporters 1 and 2.
    Gebauer L; Arul Murugan N; Jensen O; Brockmöller J; Rafehi M
    Biochem Pharmacol; 2022 Mar; 197():114871. PubMed ID: 34902340
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Simulations of biased agonists in the β(2) adrenergic receptor with accelerated molecular dynamics.
    Tikhonova IG; Selvam B; Ivetac A; Wereszczynski J; McCammon JA
    Biochemistry; 2013 Aug; 52(33):5593-603. PubMed ID: 23879802
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stereochemistry of an agonist determines coupling preference of beta2-adrenoceptor to different G proteins in cardiomyocytes.
    Woo AY; Wang TB; Zeng X; Zhu W; Abernethy DR; Wainer IW; Xiao RP
    Mol Pharmacol; 2009 Jan; 75(1):158-65. PubMed ID: 18838481
    [TBL] [Abstract][Full Text] [Related]  

  • 28. GPCRs through the keyhole: the role of protein flexibility in ligand binding to β-adrenoceptors.
    Emtage AL; Mistry SN; Fischer PM; Kellam B; Laughton CA
    J Biomol Struct Dyn; 2017 Sep; 35(12):2604-2619. PubMed ID: 27532213
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mapping the functional binding sites of cholesterol in β2-adrenergic receptor by long-time molecular dynamics simulations.
    Cang X; Du Y; Mao Y; Wang Y; Yang H; Jiang H
    J Phys Chem B; 2013 Jan; 117(4):1085-94. PubMed ID: 23298417
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stereochemical and conformational study on fenoterol by ECD spectroscopy and TD-DFT calculations.
    Tedesco D; Zanasi R; Wainer IW; Bertucci C
    J Pharm Biomed Anal; 2014 Mar; 91():92-6. PubMed ID: 24441217
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhanced G(i) signaling selectively negates beta2-adrenergic receptor (AR)--but not beta1-AR-mediated positive inotropic effect in myocytes from failing rat hearts.
    Xiao RP; Zhang SJ; Chakir K; Avdonin P; Zhu W; Bond RA; Balke CW; Lakatta EG; Cheng H
    Circulation; 2003 Sep; 108(13):1633-9. PubMed ID: 12975249
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cannabinoid receptor activation correlates with the proapoptotic action of the β2-adrenergic agonist (R,R')-4-methoxy-1-naphthylfenoterol in HepG2 hepatocarcinoma cells.
    Paul RK; Ramamoorthy A; Scheers J; Wersto RP; Toll L; Jimenez L; Bernier M; Wainer IW
    J Pharmacol Exp Ther; 2012 Oct; 343(1):157-66. PubMed ID: 22776956
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differences between G-Protein-Stabilized Agonist-GPCR Complexes and their Nanobody-Stabilized Equivalents.
    Saleh N; Ibrahim P; Clark T
    Angew Chem Int Ed Engl; 2017 Jul; 56(31):9008-9012. PubMed ID: 28481446
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structural basis for ligand binding and specificity in adrenergic receptors: implications for GPCR-targeted drug discovery.
    Huber T; Menon S; Sakmar TP
    Biochemistry; 2008 Oct; 47(42):11013-23. PubMed ID: 18821775
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Studies on the interactions between β2 adrenergic receptor and Gs protein by molecular dynamics simulations.
    Feng Z; Hou T; Li Y
    J Chem Inf Model; 2012 Apr; 52(4):1005-14. PubMed ID: 22404225
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identifying ligand binding conformations of the β2-adrenergic receptor by using its agonists as computational probes.
    Isin B; Estiu G; Wiest O; Oltvai ZN
    PLoS One; 2012; 7(12):e50186. PubMed ID: 23300522
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Membrane-Facilitated Receptor Access and Binding Mechanisms of Long-Acting
    Szlenk CT; Gc JB; Natesan S
    Mol Pharmacol; 2021 Oct; 100(4):406-427. PubMed ID: 34334369
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Probing the beta2 adrenoceptor binding site with catechol reveals differences in binding and activation by agonists and partial agonists.
    Swaminath G; Deupi X; Lee TW; Zhu W; Thian FS; Kobilka TS; Kobilka B
    J Biol Chem; 2005 Jun; 280(23):22165-71. PubMed ID: 15817484
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of intracellular loop 3 on intrinsic dynamics of human β2-adrenergic receptor.
    Ozcan O; Uyar A; Doruker P; Akten ED
    BMC Struct Biol; 2013 Nov; 13():29. PubMed ID: 24206668
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Computational design and characterization of nanobody-derived peptides that stabilize the active conformation of the β
    Sencanski M; Glisic S; Šnajder M; Veljkovic N; Poklar Ulrih N; Mavri J; Vrecl M
    Sci Rep; 2019 Nov; 9(1):16555. PubMed ID: 31719570
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.